Crohn’s disease

Abivax presented significant findings on obefazimod at ECCO 2026, revealing its anti-fibrotic activity. Preclinical data demonstrated obefazimod’s potential to combat fibrosis, a key factor in IBD complications. This complements existing clinical data showing efficacy and a favorable safety profile in IBD patients. The dual focus on inflammation and fibrosis positions obefazimod as a potentially transformative therapy for a significant unmet need.